F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: Influence on neuronal firing and neurotransmitter release

2009 ◽  
Vol 607 (1-3) ◽  
pp. 74-83 ◽  
Author(s):  
Marie-Bernadette Assié ◽  
Ouissame Mnie-Filali ◽  
Véronique Ravailhe ◽  
Christelle Benas ◽  
Marc Marien ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Neurotransmitter Release ◽  
Receptor Agonist ◽  
Partial Agonist ◽  
Neuronal Firing ◽  
D3 Receptor ◽  
Dopamine D4 Receptor ◽  
Dopamine D2 ◽  
D4 Receptor

Dopamine and intertemporal choice in humans

2018 ◽  
Vol 29 (2) ◽  
pp. 81-88
Author(s):  
Thomas F. Münte ◽  
Zheng Ye ◽  
Josep Marco-Pallarés ◽  
Ulrike M. Krämer ◽  
Rebecca Schüle ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
Intertemporal Choice ◽  
Receptor Gene ◽  
Cost Benefit ◽  
D3 Receptor ◽  
Dopamine D4 Receptor ◽  
Double Blind ◽  
Dopamine D2 ◽  
Delayed Reward ◽  
D4 Receptor

Abstract. The dopamine (DA) system has been implicated in the mediation of cost/benefit evaluations involved in the intertemporal choices between immediate and delayed rewards. This involvement was further investigated in two studies of normal participants that had to decide between a smaller immediate and a larger delayed reward in a series of 27 decisions.In study 1 the dopamine D2/D3 receptor agonist pramipexole or placebo were administered in a double-blind cross-over protocol prior to the decisions. In study 2 the same experiment was conducted in two groups of normal participants that were homozygous for either the 7repeat or the 4 repeat variant of the exon III polymorphism of the Dopamine D4 receptor gene. Dopaminergic involvement is highlighted by the results.

Sign in / Sign up

Export Citation Format

Share Document